Efficacy and safety of immune checkpoint inhibitors for locoregionally advanced, recurrent and metastatic nasopharyngeal carcinoma: a systematic review of phase III randomised controlled trials.

Naunyn Schmiedebergs Arch Pharmacol · 2026 · PMC12901119 · PMID 40952475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

2023b )/tislelizumab suggests a positive trend for OS, a longer follow-up would provide a clearer picture.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.